Palliative Care

  • Solomon LiaoEmail author
  • Rosene D. Pirrello
  • Rebecca Liddicoat Yamarik
  • Jamie Capasso


Women with gynecological cancers deserve to have their pain and symptoms managed throughout the course of their illness. This chapter discusses the essentials of pain and symptom management that a physician needs to provide quality primary palliative care for these patients. The first half of this chapter discusses opioids, their conversion, and non-opioid pain management, such as anti-inflammatories and neuropathic pain agents. The rest of the chapter discusses the management of common symptoms, such as depression, constipation, nausea and vomiting, bowel obstruction, ascites, and dyspnea. The discussion emphasizes a practical and systematic approach to symptom management. For example, the recommendation of an antidepressant is based on matching the beneficial side effects to the patients’ other problems. The relative advantages and disadvantages of laxatives are presented to aid in the selection of a laxative the patient will take. Treatment suggestions are offered for refractory constipation. Structured approaches are provided for the management of nausea, vomiting and dyspnea. Treatment options for bowel obstructions and ascites are given in the context of their pathophysiology and based on risks and benefits.


Palliative care Pain management Symptom management Comfort care Depression Constipation Bowel obstruction Ascites 


  1. 1.
    WHO Definition of Palliative Care. Accessed 5 June 2014.
  2. 2.
    Pantilet S, Anderson W, Gonzales M, et al. Hospital-based palliative medicine: a practical, evidence-based approach. Copyright © 2015 by John Wiley & Sons, Inc. Pre-publication.Google Scholar
  3. 3.
    Ferris and Pirrello. Improving equianalgesic dosing for chronic pain management. American Association for Cancer Education Annual Meeting Presentation, Cincinnati, OH, Sept 2005.Google Scholar
  4. 4.
    Attal N, Cruccu G, Baron R, Haanpää M, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88.PubMedCrossRefGoogle Scholar
  5. 5.
    Chase DM, Monk BJ, et al. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008;8(2):227–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Kirkova J, Davis MP, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24:1459–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Chochinov HM, Wilson KG, et al. Are you depressed? screening for depression in the terminally ill. Am J Psychiatry. 1997;154:674–6.PubMedGoogle Scholar
  8. 8.
    Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. J Clin Oncol. 2012;30:1187–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary general anxiety disorders or comorbid with mood disorders. Expert Rev Neurother. 2009;9(8):1147–58.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage. 2013;45(1):2–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Thomas J, Karver S, Cooney GA, Chamberlain BH, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Pothuri B, Montemarano M, Gerardi M, Shike M, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96(2):330–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Matulonis UA, Seiden MV, Roche M, Krasner C, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44(8):1105–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Ripamonti C, Twycross R, Baines M, Bozzetti F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223–33.PubMedCrossRefGoogle Scholar
  16. 16.
    de Bree E, Koops W, Kröger R, van Ruth S, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Rath KS, Loseth D, Muscarella P, Phillips GS, et al. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecol Oncol. 2013;129(1):103–6.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Harding V, Fenu E, Medani H, Shaboodien R, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 2012;107(6):925–30.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage. 2009;38(3):341–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29(8):3353–9.PubMedGoogle Scholar
  23. 23.
    Runyon BA. Management of adult patients with ascites due to cirrhosis: update. 2012. Accessed 11/12/13.
  24. 24.
    Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87–95.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96(9):1157–8.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38(5):484–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73(9):449–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med. 2008;11(2):204–16.PubMedCrossRefGoogle Scholar
  34. 34.
    Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severedyspnea in hospitalized patients receiving palliative care. J Pain Symptom Manage. 2013;45(5):885–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Davidson PM, Johnson MJ. Update on the role of palliative oxygen. Curr Opin Support Palliat Care. 2011;5(2):87–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Solomon Liao
    • 1
    Email author
  • Rosene D. Pirrello
    • 2
  • Rebecca Liddicoat Yamarik
    • 3
  • Jamie Capasso
    • 1
  1. 1.Department of Internal Medicine, Irvine Medical CenterUniversity of CaliforniaOrangeUSA
  2. 2.Department of Pharmacy Services, UC Irvine Health Department of Pharmacy Services, Irvine Medical CenterUniversity of CaliforniaOrangeUSA
  3. 3.Providence Trinity Care HospiceTorranceUSA

Personalised recommendations